bioMerieux (OTCMKTS:BMXMF) Upgraded to “Hold” at Zacks Research

Posted by Joseph Casey on Sep 30th, 2026

bioMerieux (OTCMKTS:BMXMF – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

Several other analysts have also commented on the stock. Piper Sandler started coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Finally, Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Five investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Check Out Our Latest Research Report on bioMerieux

bioMerieux Stock Performance

Shares of BMXMF opened at $83.27 on Monday. The company has a 50 day moving average price of $82.98 and a 200-day moving average price of $87.89. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08. bioMerieux has a fifty-two week low of $77.00 and a fifty-two week high of $138.15.

bioMerieux Company Profile

(Get Free Report)

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.